Receptos
Receptos was a San Diego-based clinical-stage biopharmaceutical company (founded 2007) that developed therapeutics for immune disorders, most notably the S1P receptor modulator ozanimod. Acquired by Celgene for ~$7.2B in 2015 and subsequently absorbed into Bristol Myers Squibb.
- Company typePrivate
- Founded2007
- HeadquartersSan Diego, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Receptos does
Receptos was a clinical-stage biopharmaceutical company founded in 2007 and headquartered in San Diego, California. The company focused on the discovery, development, and intended commercialization of therapeutics for immune disorders, with its pipeline anchored on S1P receptor modulator chemistry, most prominently ozanimod for multiple sclerosis and other inflammatory indications. Receptos operated with a headcount in the 51-100 range, financed through roughly $73.5M of venture capital across 2009-2014 from ARCH Venture Partners, Flagship Pioneering, Lilly Ventures, OrbiMed, OUP, Polaris Partners, and Venrock, and had listed on NASDAQ under ticker RCPT prior to its acquisition.
In August 2015 Receptos was acquired by Celgene Corporation for approximately $7.2 billion, ending its standalone operations. Celgene was subsequently acquired by Bristol Myers Squibb in November 2019, and Receptos' assets - most importantly the ozanimod franchise - sit today within BMS's immunology portfolio alongside a broader pipeline of 50 compounds across 40+ disease areas. Because the company did not exist as an independent commercial entity at acquisition, there are no standalone revenue mechanics, pricing models, or customer relationships to characterize; the relevant economic and commercial dynamics are now those of BMS's immunology franchise rather than the legacy Receptos organization.
Receptos firmographics
Firmographics- Name
- Receptos
- Website
- https://receptos.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Receptos was a San Diego-based clinical-stage biopharmaceutical company (founded 2007) that developed therapeutics for immune disorders, most notably the S1P receptor modulator ozanimod. Acquired by Celgene for ~$7.2B in 2015 and subsequently absorbed into Bristol Myers Squibb.
- Ownership category
- akta.pro rank
Receptos industry classification
Industry- Product category
- Immunology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
Keywords
Where Receptos is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
Receptos business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Distribution channels3 records
Marketing channels9 records
Receptos product offering
Product offeringCore offering
Receptos is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics for immune disorders. The company develops drug candidates that selectively target and eliminate disease-causing proteins through protein degradation science and related biopharmaceutical research approaches. Its work spans clinical-stage immunology drug development leveraging AI-driven discovery platforms.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- 50 compounds in development targeting transformative medicines
- +2 more outcomes
Companies that use Receptos
Customer profileSegments6 records
Ideal customer profiles1 record
Receptos technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Receptos partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights3 records
Receptos competitors and assessment
Company assessmentMarket position
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
Receptos social profiles
Digital presenceReceptos financial estimates
Financial estimateRevenue estimate
Valuation estimate
Receptos leadership team
Management profileNumber of profiles
Receptos funding detail
Funding detailFunding overview
Funding rounds6 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Receptos M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Receptos
What does Receptos do?
Receptos is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics for immune disorders. The company develops drug candidates that selectively target and eliminate disease-causing proteins through protein degradation science and related biopharmaceutical research approaches. Its work spans clinical-stage immunology drug development leveraging AI-driven discovery platforms.
Is Receptos a public or private company?
Receptos is a private company. It is classified as corporate owned and is currently acquired.
When was Receptos founded?
Receptos was founded in 2007. It employs 51 to 100 people.
Where is Receptos based?
Receptos is headquartered in San Diego, United States, in the North America region.
Does Receptos have an API?
No public API is recorded for Receptos.
What industry is Receptos in?
Receptos's product category is Immunology Therapeutics. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 541714.